Browsing by Author "Turkoglu, Recai"
Now showing items 1-7 of 7
-
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis
Boz, Cavit; Terzi, Murat; Ozer, Bilge; Turkoglu, Recai; Karabudak, Rana; Efendi, Husnu; Ozakbas, Serkan (Elsevier Sci Ltd, 2019)Background: Fingolimod and teriflunomide are commonly used in the treatment of relapsing-remitting multiple sclerosis (RRMS). These have not been compared in controlled trials, but only in observational studies, with ... -
Comparison of the Cytokine Profiles of Patients With Neuronal-Antibody-Associated Central Nervous System Disorders
Ulusoy, Canan; Tuzun, Erdem; Kurtuncu, Murat; Turkoglu, Recai; Akman-Demir, Gulsen; Eraksoy, Mefkure (INFORMA HEALTHCARE, 2012)Levels of several cytokines were evaluated in the sera of patients with neuromyelitis optica (NMO) and paraneoplastic or nonparaneoplastic autoimmune encephalitis (AE) and healthy controls (HC). AE patients had higher serum ... -
CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients
Karaaslan, Zerrin; Kurtuncu, Murat; Akcay, Halil Ibrahim; Gunduz, Tuncay; Altunrende, Burcu; Turkoglu, Recai; Eraksoy, Mefkure (Karger, 2021)[No Abstract Availale] -
Effect of short-term interferon-beta treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23
Kurtuncu, Murat; Tuzun, Erdem; Turkoglu, Recai; Petek-Balci, Belgin; Icoz, Sema; Pehlivan, Munevver; Eraksoy, Mefkure (ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2012)Therapeutic effect of interferon-beta (IFN-beta) treatment has been associated with modulation of the balance between Th1, Th17, Th2 and regulatory T (Treg) cells, whereas the impact of disease modifying drugs on Th9-immunity ... -
Effects of Fingolimod on Cytokine and Chemokine Levels in Patients with Multiple Sclerosis
Kurtuncu, Murat; Yilmaz, Vuslat; Akcay, Halil Ibrahim; Turkoglu, Recai; Altunrende, Burcu; Ulusoy, Canan; Tuzun, Erdem (LIPPINCOTT WILLIAMS & WILKINS, 2019)… -
Impact of fingolimod on CD4+T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients
Kurtuncu, Murat; Yilmaz, Vuslat; Akcay, Halil Ibrahim; Turkoglu, Recai; Altunrende, Burcu; Cinar, Suzan Adin; Tuzun, Erdem (Elsevier, 2019)Fingolimod inhibits the egress of lymphocytes from lymphatic tissues and also directly affects their functions by modulation of the sphingosine-1 -phosphate receptor 1 (S1P1). Our aim was to evaluate the impact of fingolimod ... -
Predictive value of early serum cytokine changes on long-term interferon beta-1a efficacy in multiple sclerosis
Petek-Balci, Belgin; Coban, Arzu; Shugaiv, Erkingul; Turkoglu, Recai; Ulusoy, Canan; Icoz, Sema; Eraksoy, Mefkure (INFORMA HEALTHCARE, 2015)Background: In a previous study, we had evaluated short-term effects of interferon beta-1a (IFNB-1a) 44 mu g s.c. three times per week treatment on serum levels of IFN-gamma (IFNG), IL-23, IL-17, IL-10, IL-9, IL-4 and ...